| Agenus is a clinical-stage immuno-oncology (I-O) company engaged in the development of a pipeline of immune checkpoint antibodies, adoptive cell therapies and neoantigen cancer vaccines, to fight cancer. Co.'s antibody candidates are balstilimab and zalifrelimab (an anti-CTLA-4 antibody), which are in Phase 2 trials as both a monotherapy (balstilimab) and combination therapy (balstilimab/zalifrelimab) for treatment of patients with second-line cervical cancer. Co. is also developing an anti-CTLA-4 antibody, AGEN1181, which is designed to enhance the magnitude of responses to first-generation anti-CTLA-4 molecules and to expand the population of patients benefiting from anti-CTLA-4 therapy. We show 38 historical shares outstanding datapoints in our AGEN shares outstanding history coverage, used to compute AGEN market cap on those dates.|
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing AGEN market cap history over the course of time is important for investors
interested in comparing AGEN's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of AGEN versus a peer is one thing; comparing
AGEN market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like AGEN can fluctuate over the course of history.
With this page we aim to empower investors researching AGEN by allowing them to research the AGEN market cap history.